BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76:582-588. [PMID: 18619946 DOI: 10.1016/j.bcp.2008.06.007] [Cited by in Crossref: 328] [Cited by in F6Publishing: 307] [Article Influence: 23.4] [Reference Citation Analysis]
Number Citing Articles
1 Katayama K, Noguchi K, Sugimoto Y. Regulations of P-Glycoprotein/ABCB1/ MDR1 in Human Cancer Cells. New Journal of Science 2014;2014:1-10. [DOI: 10.1155/2014/476974] [Cited by in Crossref: 58] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
2 Chhabra R, Dubey R, Saini N. Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases. Mol Cancer. 2010;9:232. [PMID: 20815877 DOI: 10.1186/1476-4598-9-232] [Cited by in Crossref: 233] [Cited by in F6Publishing: 220] [Article Influence: 19.4] [Reference Citation Analysis]
3 Yu A. Role of microRNAs in the regulation of drug metabolism and disposition. Expert Opinion on Drug Metabolism & Toxicology 2009;5:1513-28. [DOI: 10.1517/17425250903307448] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
4 Catani MV, Savini I, Tullio V, Gasperi V. The "Janus Face" of Platelets in Cancer. Int J Mol Sci. 2020;21. [PMID: 31991775 DOI: 10.3390/ijms21030788] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
5 Bach DH, Hong JY, Park HJ, Lee SK. The role of exosomes and miRNAs in drug-resistance of cancer cells. Int J Cancer 2017;141:220-30. [PMID: 28240776 DOI: 10.1002/ijc.30669] [Cited by in Crossref: 123] [Cited by in F6Publishing: 130] [Article Influence: 24.6] [Reference Citation Analysis]
6 La X, Zhang L, Li Z, Li H, Yang Y. (-)-Epigallocatechin Gallate (EGCG) Enhances the Sensitivity of Colorectal Cancer Cells to 5-FU by Inhibiting GRP78/NF-κB/miR-155-5p/MDR1 Pathway. J Agric Food Chem 2019;67:2510-8. [PMID: 30741544 DOI: 10.1021/acs.jafc.8b06665] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
7 Moitra K, Im K, Limpert K, Borsa A, Sawitzke J, Robey R, Yuhki N, Savan R, Huang da W, Lempicki RA, Bates S, Dean M. Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012;7:e45268. [PMID: 23028896 DOI: 10.1371/journal.pone.0045268] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
8 Li Y, Zhu X, Gu J, Dong D, Yao J, Lin C, Huang K, Fei J. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci 2010;101:948-54. [PMID: 20148895 DOI: 10.1111/j.1349-7006.2010.01489.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
9 Maia RC, Vasconcelos FC, Souza PS, Rumjanek VM. Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia. Molecules 2018;23:E119. [PMID: 29316665 DOI: 10.3390/molecules23010119] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
10 Boissière A, Gala A, Ferrières-Hoa A, Mullet T, Baillet S, Petiton A, Torre A, Hamamah S. Cell-free and intracellular nucleic acids: new non-invasive biomarkers to explore male infertility. Basic Clin Androl 2017;27:7. [PMID: 28439417 DOI: 10.1186/s12610-017-0052-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
11 Aronica E, Sisodiya SM, Gorter JA. Cerebral expression of drug transporters in epilepsy. Adv Drug Deliv Rev 2012;64:919-29. [PMID: 22138133 DOI: 10.1016/j.addr.2011.11.008] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
12 Wong L, You ZH, Guo ZH, Yi HC, Chen ZH, Cao MY. MIPDH: A Novel Computational Model for Predicting microRNA-mRNA Interactions by DeepWalk on a Heterogeneous Network. ACS Omega 2020;5:17022-32. [PMID: 32715187 DOI: 10.1021/acsomega.9b04195] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
13 Donzelli S, Mori F, Biagioni F, Bellissimo T, Pulito C, Muti P, Strano S, Blandino G. MicroRNAs: short non-coding players in cancer chemoresistance. Mol Cell Ther 2014;2:16. [PMID: 26056584 DOI: 10.1186/2052-8426-2-16] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
14 Bach DH, Kim D, Bae SY, Kim WK, Hong JY, Lee HJ, Rajasekaran N, Kwon S, Fan Y, Luu TT, Shin YK, Lee J, Lee SK. Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells. Mol Ther Nucleic Acids 2018;11:455-67. [PMID: 29858080 DOI: 10.1016/j.omtn.2018.03.011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
15 Gong J, Jaiswal R, Mathys J, Combes V, Grau G, Bebawy M. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treatment Reviews 2012;38:226-34. [DOI: 10.1016/j.ctrv.2011.06.005] [Cited by in Crossref: 108] [Cited by in F6Publishing: 99] [Article Influence: 10.8] [Reference Citation Analysis]
16 Carta A, Chetcuti R, Ayers D. An Introspective Update on the Influence of miRNAs in Breast Carcinoma and Neuroblastoma Chemoresistance. Genet Res Int 2014;2014:743050. [PMID: 25548681 DOI: 10.1155/2014/743050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
17 Zhu X, Li H, Long L, Hui L, Chen H, Wang X, Shen H, Xu W. miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin (Shanghai). 2012;44:519-526. [PMID: 22510476 DOI: 10.1093/abbs/gms026] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 7.9] [Reference Citation Analysis]
18 Tomiyasu H, Tsujimoto H. Comparative Aspects of Molecular Mechanisms of Drug Resistance through ABC Transporters and Other Related Molecules in Canine Lymphoma. Vet Sci 2015;2:185-205. [PMID: 29061940 DOI: 10.3390/vetsci2030185] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
19 Ban JJ, Chung JY, Lee M, Im W, Kim M. MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease. Biochem Biophys Res Commun 2017;488:316-21. [PMID: 28495533 DOI: 10.1016/j.bbrc.2017.05.040] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
20 Andrikopoulou A, Shalit A, Zografos E, Koutsoukos K, Korakiti AM, Liontos M, Dimopoulos MA, Zagouri F. MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment. Cancers (Basel) 2021;13:4114. [PMID: 34439268 DOI: 10.3390/cancers13164114] [Reference Citation Analysis]
21 Ikemura K, Yamamoto M, Miyazaki S, Mizutani H, Iwamoto T, Okuda M. MicroRNA-145 post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cells. Mol Pharmacol 2013;83:399-405. [PMID: 23166305 DOI: 10.1124/mol.112.081844] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 5.5] [Reference Citation Analysis]
22 Saito J, Hirota T, Furuta S, Kobayashi D, Takane H, Ieiri I. Association between DNA methylation in the miR-328 5'-flanking region and inter-individual differences in miR-328 and BCRP expression in human placenta. PLoS One 2013;8:e72906. [PMID: 23991164 DOI: 10.1371/journal.pone.0072906] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
23 Bruhn O, Drerup K, Kaehler M, Haenisch S, Röder C, Cascorbi I. Length variants of the ABCB1 3′-UTR and loss of miRNA binding sites: possible consequences in regulation and pharmacotherapy resistance. Pharmacogenomics 2016;17:327-40. [DOI: 10.2217/pgs.15.175] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
24 Koshkin PA, Chistiakov DA, Chekhonin VP. Role of microRNAs in mechanisms of glioblastoma resistance to radio- and chemotherapy. Biochemistry Moscow 2013;78:325-34. [DOI: 10.1134/s0006297913040019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
25 Zhao L, Bin S, He HL, Yang JM, Pu YC, Gao CH, Wang H, Wang BL. Sodium butyrate increases P-gp expression in lung cancer by upregulation of STAT3 and mRNA stabilization of ABCB1. Anticancer Drugs 2018;29:227-33. [PMID: 29293118 DOI: 10.1097/CAD.0000000000000588] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Fonsato V, Collino F, Herrera MB, Cavallari C, Deregibus MC, Cisterna B, Bruno S, Romagnoli R, Salizzoni M, Tetta C, Camussi G. Human liver stem cell-derived microvesicles inhibit hepatoma growth in SCID mice by delivering antitumor microRNAs. Stem Cells 2012;30:1985-98. [PMID: 22736596 DOI: 10.1002/stem.1161] [Cited by in Crossref: 118] [Cited by in F6Publishing: 113] [Article Influence: 13.1] [Reference Citation Analysis]
27 Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O, Cascorbi I. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics 2012;22:198-205. [PMID: 22241070 DOI: 10.1097/FPC.0b013e328350012b] [Cited by in Crossref: 54] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
28 Maire G, Martin JW, Yoshimoto M, Chilton-MacNeill S, Zielenska M, Squire JA. Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet 2011;204:138-46. [PMID: 21504713 DOI: 10.1016/j.cancergen.2010.12.012] [Cited by in Crossref: 89] [Cited by in F6Publishing: 87] [Article Influence: 8.1] [Reference Citation Analysis]
29 Henry JC, Azevedo-pouly ACP, Schmittgen TD. microRNA Replacement Therapy for Cancer. Pharm Res 2011;28:3030-42. [DOI: 10.1007/s11095-011-0548-9] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 8.2] [Reference Citation Analysis]
30 Li MM, Wang WP, Wu WJ, Huang M, Yu AM. Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells. Drug Metab Dispos 2014;42:1791-5. [PMID: 25161167 DOI: 10.1124/dmd.114.060145] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
31 Nakajima M, Yokoi T. MicroRNAs from biology to future pharmacotherapy: Regulation of cytochrome P450s and nuclear receptors. Pharmacology & Therapeutics 2011;131:330-7. [DOI: 10.1016/j.pharmthera.2011.04.009] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
32 San José-Enériz E, Román-Gómez J, Jiménez-Velasco A, Garate L, Martin V, Cordeu L, Vilas-Zornoza A, Rodríguez-Otero P, Calasanz MJ, Prósper F, Agirre X. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Mol Cancer 2009;8:69. [PMID: 19723306 DOI: 10.1186/1476-4598-8-69] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 6.6] [Reference Citation Analysis]
33 Feng DD, Zhang H, Zhang P, Zheng YS, Zhang XJ, Han BW, Luo XQ, Xu L, Zhou H, Qu LH, Chen YQ. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med. 2011;15:2164-2175. [PMID: 21070600 DOI: 10.1111/j.1582-4934.2010.01213.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 11.3] [Reference Citation Analysis]
34 An X, Sarmiento C, Tan T, Zhu H. Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sin B 2017;7:38-51. [PMID: 28119807 DOI: 10.1016/j.apsb.2016.09.002] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 14.7] [Reference Citation Analysis]
35 Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillhardt M, Hua YJ, Lengyel E, Peter ME. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer 2012;130:1787-97. [PMID: 21618519 DOI: 10.1002/ijc.26190] [Cited by in Crossref: 104] [Cited by in F6Publishing: 98] [Article Influence: 9.5] [Reference Citation Analysis]
36 Balch C, Matei DE, Huang TH, Nephew KP. Role of epigenomics in ovarian and endometrial cancers. Epigenomics 2010;2:419-47. [PMID: 22121902 DOI: 10.2217/epi.10.19] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
37 Xu M, Deng H, Li H. MicroRNA-27a regulates angiotensin II-induced vascular smooth muscle cell proliferation and migration by targeting α-smooth muscle-actin in vitro. Biochemical and Biophysical Research Communications 2019;509:973-7. [DOI: 10.1016/j.bbrc.2019.01.047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
38 Xu K, Liang X, Cui D, Wu Y, Shi W, Liu J. miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol Carcinog 2013;52:70-8. [DOI: 10.1002/mc.21832] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 6.3] [Reference Citation Analysis]
39 Uribe JH, Collado-Romero M, Zaldívar-López S, Arce C, Bautista R, Carvajal A, Cirera S, Claros MG, Garrido JJ. Transcriptional analysis of porcine intestinal mucosa infected with Salmonella Typhimurium revealed a massive inflammatory response and disruption of bile acid absorption in ileum. Vet Res 2016;47:11. [PMID: 26738723 DOI: 10.1186/s13567-015-0286-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
40 He Y, Chevillet JR, Liu G, Kim TK, Wang K. The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs. Br J Pharmacol 2015;172:2733-47. [PMID: 25296724 DOI: 10.1111/bph.12968] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
41 Gromicho M, Dinis J, Magalhães M, Fernandes AR, Tavares P, Laires A, Rueff J, Rodrigues AS. Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk Lymphoma 2011;52:1980-90. [PMID: 21663515 DOI: 10.3109/10428194.2011.584005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
42 Yin W, Wang P, Wang X, Song W, Cui X, Yu H, Zhu W. Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells. Braz J Med Biol Res 2013;46:546-54. [PMID: 23780424 DOI: 10.1590/1414-431X20131662] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
43 Langhe R. microRNA and Ovarian Cancer. In: Santulli G, editor. microRNA: Cancer. Cham: Springer International Publishing; 2015. pp. 119-51. [DOI: 10.1007/978-3-319-23730-5_8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
44 Yu AM, Pan YZ. Noncoding microRNAs: small RNAs play a big role in regulation of ADME? Acta Pharm Sin B 2012;2:93-101. [PMID: 32154096 DOI: 10.1016/j.apsb.2012.02.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
45 Erbes T, Hirschfeld M, Rücker G, Jaeger M, Boas J, Iborra S, Mayer S, Gitsch G, Stickeler E. Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker. BMC Cancer. 2015;15:193. [PMID: 25886191 DOI: 10.1186/s12885-015-1190-4] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 10.0] [Reference Citation Analysis]
46 Dai X, Tan C. Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers. Adv Drug Deliv Rev 2015;81:184-97. [PMID: 25281917 DOI: 10.1016/j.addr.2014.09.010] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 11.1] [Reference Citation Analysis]
47 Yang R, Schlehe B, Hemminki K, Sutter C, Bugert P, Wappenschmidt B, Volkmann J, Varon R, Weber BH, Niederacher D. A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. Breast Cancer Res Treat. 2010;121:693-702. [PMID: 19921425 DOI: 10.1007/s10549-009-0633-5] [Cited by in Crossref: 89] [Cited by in F6Publishing: 87] [Article Influence: 6.8] [Reference Citation Analysis]
48 Smith RP, Lam ET, Markova S, Yee SW, Ahituv N. Pharmacogene regulatory elements: from discovery to applications. Genome Med 2012;4:45. [PMID: 22630332 DOI: 10.1186/gm344] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
49 Brodziak A, Sobczuk P, Bartnik E, Fiedorowicz M, Porta C, Szczylik C, Czarnecka AM. Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. Nat Rev Urol 2019;16:655-73. [PMID: 31602010 DOI: 10.1038/s41585-019-0233-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
50 Nordentoft I, Birkenkamp-Demtroder K, Agerbæk M, Theodorescu D, Ostenfeld MS, Hartmann A, Borre M, Ørntoft TF, Dyrskjøt L. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics 2012;5:40. [PMID: 22954303 DOI: 10.1186/1755-8794-5-40] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
51 Szkolnicka D, Lucendo-Villarin B, Moore JK, Simpson KJ, Forbes SJ, Hay DC. Reducing Hepatocyte Injury and Necrosis in Response to Paracetamol Using Noncoding RNAs. Stem Cells Transl Med 2016;5:764-72. [PMID: 27057006 DOI: 10.5966/sctm.2015-0117] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
52 Mcintosh K, Balch C, Tiwari AK. Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells. Expert Opinion on Drug Metabolism & Toxicology 2016;12:633-44. [DOI: 10.1080/17425255.2016.1179280] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
53 Lu JF, Luk F, Gong J, Jaiswal R, Grau GE, Bebawy M. Microparticles mediate MRP1 intercellular transfer and the re-templating of intrinsic resistance pathways. Pharmacol Res 2013;76:77-83. [PMID: 23917219 DOI: 10.1016/j.phrs.2013.07.009] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
54 Schuetz TA, Becker S, Mang A, Toma A, Buzug TM. Modelling of glioblastoma growth by linking a molecular interaction network with an agent-based model. Mathematical and Computer Modelling of Dynamical Systems 2013;19:417-33. [DOI: 10.1080/13873954.2013.777748] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
55 Sousa D, Matthiesen R, Lima RT, Vasconcelos MH. Deep Sequencing Analysis Reveals Distinctive Non-Coding RNAs When Comparing Tumor Multidrug-Resistant Cells and Extracellular Vesicles with Drug-Sensitive Counterparts. Cancers (Basel) 2020;12:E200. [PMID: 31947507 DOI: 10.3390/cancers12010200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
56 Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z, Liu J, Cui Y, Bian X, Bie P, Qian C. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Letters 2011. [DOI: 10.1016/j.canlet.2011.06.027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 93] [Article Influence: 2.0] [Reference Citation Analysis]
57 Kent OA, McCall MN, Cornish TC, Halushka MK. Lessons from miR-143/145: the importance of cell-type localization of miRNAs. Nucleic Acids Res 2014;42:7528-38. [PMID: 24875473 DOI: 10.1093/nar/gku461] [Cited by in Crossref: 134] [Cited by in F6Publishing: 122] [Article Influence: 16.8] [Reference Citation Analysis]
58 Yahya SM, Elsayed GH. A summary for molecular regulations of miRNAs in breast cancer. Clin Biochem 2015;48:388-96. [PMID: 25541018 DOI: 10.1016/j.clinbiochem.2014.12.013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
59 Khawar MB, Mehmood R, Roohi N. MicroRNAs: Recent insights towards their role in male infertility and reproductive cancers. Bosn J Basic Med Sci 2019;19:31-42. [PMID: 30599090 DOI: 10.17305/bjbms.2018.3477] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
60 La Rosa G, Biasucci LM, Mandolini C, Massimi I, Copponi G, Pulcinelli FM, Crea F. Platelet miRNA-26b down-regulates multidrug resistance protein 4 in patients on chronic aspirin treatment. J Cardiovasc Med (Hagerstown) 2018;19:611-3. [PMID: 30015780 DOI: 10.2459/JCM.0000000000000691] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
61 Li X, Xu M, Ding L, Tang J. MiR-27a: A Novel Biomarker and Potential Therapeutic Target in Tumors. J Cancer 2019;10:2836-48. [PMID: 31258791 DOI: 10.7150/jca.31361] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 12.7] [Reference Citation Analysis]
62 Del Follo-martinez A, Banerjee N, Li X, Safe S, Mertens-talcott S. Resveratrol and Quercetin in Combination Have Anticancer Activity in Colon Cancer Cells and Repress Oncogenic microRNA-27a. Nutrition and Cancer 2013;65:494-504. [DOI: 10.1080/01635581.2012.725194] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 10.3] [Reference Citation Analysis]
63 Liu M, Zhang X, Hu CF, Xu Q, Zhu HX, Xu NZ. MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells. Chin J Cancer 2014;33:285-94. [PMID: 24589211 DOI: 10.5732/cjc.013.10136] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
64 Yang T, Zheng ZM, Li XN, Li ZF, Wang Y, Geng YF, Bai L, Zhang XB. MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp Biol Med (Maywood). 2013;238:1024-1032. [PMID: 23925649 DOI: 10.1177/1535370213497321] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 8.8] [Reference Citation Analysis]
65 Kang T, Lu W, Xu W, Anderson L, Bacanamwo M, Thompson W, Chen YE, Liu D. MicroRNA-27 (miR-27) targets prohibitin and impairs adipocyte differentiation and mitochondrial function in human adipose-derived stem cells. J Biol Chem 2013;288:34394-402. [PMID: 24133204 DOI: 10.1074/jbc.M113.514372] [Cited by in F6Publishing: 67] [Reference Citation Analysis]
66 Koturbash I, Zemp FJ, Pogribny I, Kovalchuk O. Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis. Mutat Res 2011;722:94-105. [PMID: 20472093 DOI: 10.1016/j.mrgentox.2010.05.006] [Cited by in Crossref: 87] [Cited by in F6Publishing: 70] [Article Influence: 7.3] [Reference Citation Analysis]
67 Li J, Yang X, Guan H, Mizokami A, Keller ET, Xu X, Liu X, Tan J, Hu L, Lu Y, Zhang J. Exosome-derived microRNAs contribute to prostate cancer chemoresistance. Int J Oncol 2016;49:838-46. [PMID: 27278879 DOI: 10.3892/ijo.2016.3560] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 8.2] [Reference Citation Analysis]
68 Ma ZL, Yang L, Chen LB, Huang JM, Wang DD, Wang GB. Differential expression profile of microRNAs in the different stages of hepatitis B virus infection-related hepatocarcinogenesis. Shijie Huaren Xiaohua Zazhi 2009; 17(20): 2112-2116 [DOI: 10.11569/wcjd.v17.i20.2112] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
69 Dai Y, Xie C, Neis JP, Fan C, Vural E, Spring PM. MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011;33:786-91. [DOI: 10.1002/hed.21540] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
70 Yuan J, Lang J, Liu C, Zhou K, Chen L, Liu Y. The expression and function of miRNA-451 in osteosarcoma. Med Oncol 2015;32:324. [PMID: 25471786 DOI: 10.1007/s12032-014-0324-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
71 Bugde P, Biswas R, Merien F, Lu J, Liu D, Chen M, Zhou S, Li Y. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. Expert Opinion on Therapeutic Targets 2017;21:511-30. [DOI: 10.1080/14728222.2017.1310841] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 12.6] [Reference Citation Analysis]
72 Alural B, Ayyildiz ZO, Tufekci KU, Genc S, Genc K. Erythropoietin Promotes Glioblastoma via miR-451 Suppression. Vitam Horm 2017;105:249-71. [PMID: 28629521 DOI: 10.1016/bs.vh.2017.03.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
73 Ingelman-sundberg M, Gomez A. The past, present and future of pharmacoepigenomics. Pharmacogenomics 2010;11:625-7. [DOI: 10.2217/pgs.10.59] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
74 Hirota T, Tanaka T, Takesue H, Ieiri I. Epigenetic regulation of drug transporter expression in human tissues. Expert Opinion on Drug Metabolism & Toxicology 2016;13:19-30. [DOI: 10.1080/17425255.2017.1230199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
75 Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther. 2010;17:523-531. [PMID: 20467450 DOI: 10.1038/cgt.2010.18] [Cited by in Crossref: 201] [Cited by in F6Publishing: 190] [Article Influence: 16.8] [Reference Citation Analysis]
76 Liang Z, Li Y, Huang K, Wagar N, Shim H. Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res. 2011;28:3091-3100. [PMID: 21853360 DOI: 10.1007/s11095-011-0570-y] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 7.4] [Reference Citation Analysis]
77 Adamska A, Falasca M. ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward? World J Gastroenterol 2018; 24(29): 3222-3238 [PMID: 30090003 DOI: 10.3748/wjg.v24.i29.3222] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 9.5] [Reference Citation Analysis]
78 Wang C, Ku P, Nie X, Bao S, Wang Z, Li K. Effects of simvastatin on the PXR signaling pathway and the liver histology in Mugilogobius abei. Science of The Total Environment 2019;651:399-409. [DOI: 10.1016/j.scitotenv.2018.09.133] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
79 Xu Y, Ohms SJ, Li Z, Wang Q, Gong G, Hu Y, Mao Z, Shannon MF, Fan JY. Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance. PLoS One 2013;8:e82062. [PMID: 24303078 DOI: 10.1371/journal.pone.0082062] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 6.1] [Reference Citation Analysis]
80 Akiyama K, Ohga N, Hida Y, Kawamoto T, Sadamoto Y, Ishikawa S, Maishi N, Akino T, Kondoh M, Matsuda A, Inoue N, Shindoh M, Hida K. Tumor Endothelial Cells Acquire Drug Resistance by MDR1 Up-Regulation via VEGF Signaling in Tumor Microenvironment. The American Journal of Pathology 2012;180:1283-93. [DOI: 10.1016/j.ajpath.2011.11.029] [Cited by in Crossref: 99] [Cited by in F6Publishing: 96] [Article Influence: 9.9] [Reference Citation Analysis]
81 Liang Z, Feng A, Shim H. MicroRNA-30c-regulated HDAC9 mediates chemoresistance of breast cancer. Cancer Chemother Pharmacol 2020;85:413-23. [PMID: 31907648 DOI: 10.1007/s00280-019-04024-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
82 Espelt MV, Bacigalupo ML, Carabias P, Troncoso MF. MicroRNAs contribute to ATP-binding cassette transporter- and autophagy-mediated chemoresistance in hepatocellular carcinoma. World J Hepatol 2019; 11(4): 344-358 [PMID: 31114639 DOI: 10.4254/wjh.v11.i4.344] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
83 Rodrigues AC, Neri EA, Veríssimo-Filho S, Rebouças NA, Hirata RD, Yu AM. Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells. Eur J Pharm Sci 2016;93:431-6. [PMID: 27575876 DOI: 10.1016/j.ejps.2016.08.044] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
84 Gomez A, Ingelman-Sundberg M. Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther. 2009;85:426-430. [PMID: 19242404 DOI: 10.1038/clpt.2009.2] [Cited by in Crossref: 81] [Cited by in F6Publishing: 63] [Article Influence: 6.2] [Reference Citation Analysis]
85 Izzotti A, Pulliero A. The effects of environmental chemical carcinogens on the microRNA machinery. Int J Hyg Environ Health 2014;217:601-27. [PMID: 24560354 DOI: 10.1016/j.ijheh.2014.01.001] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 9.9] [Reference Citation Analysis]
86 Li Z, Branham WS, Dial SL, Wang Y, Guo L, Shi L, Chen T. Genomic analysis of microRNA time-course expression in liver of mice treated with genotoxic carcinogen N-ethyl-N-nitrosourea. BMC Genomics 2010;11:609. [PMID: 21029445 DOI: 10.1186/1471-2164-11-609] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
87 Oh J, Ji SC, Lee H, Yu KS, Jang IJ. Response to "Induction of both P-glycoprotein and specific cytochrome P450 by aspirin eventually does not alter the antithrombotic effect of clopidogrel". Clin Pharmacol Ther 2015;97:325. [PMID: 25669937 DOI: 10.1002/cpt.74] [Reference Citation Analysis]
88 Motamedi M, Hashemzadeh Chaleshtori M, Ghasemi S, Mokarian F. Plasma Level Of miR-21 And miR-451 In Primary And Recurrent Breast Cancer Patients. Breast Cancer (Dove Med Press) 2019;11:293-301. [PMID: 31749630 DOI: 10.2147/BCTT.S224333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
89 Jaiswal R, Raymond Grau GE, Bebawy M. Cellular communication via microparticles: role in transfer of multidrug resistance in cancer. Future Oncol 2014;10:655-69. [PMID: 24754595 DOI: 10.2217/fon.13.230] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
90 Ding W, Cao C, Gao Y, Zhou X, Lai Y. Inhibition of CYP3A4 and CYP3A5 expression by scutellarin is not mediated via the regulation of hsa-miR-27a, 27b, 148a, 298 and 451a levels. Xenobiotica 2020;50:1267-74. [PMID: 30501535 DOI: 10.1080/00498254.2018.1555344] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Norouzi-Barough L, Sarookhani MR, Sharifi M, Moghbelinejad S, Jangjoo S, Salehi R. Molecular mechanisms of drug resistance in ovarian cancer. J Cell Physiol 2018;233:4546-62. [PMID: 29152737 DOI: 10.1002/jcp.26289] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 18.3] [Reference Citation Analysis]
92 Lin G, Xu K. [Advances in tumor chemo-resistance regulated by MicroRNA]. Zhongguo Fei Ai Za Zhi 2014;17:741-9. [PMID: 25342041 DOI: 10.3779/j.issn.1009-3419.2014.10.06] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Liu WH, Tao KS, You N, Liu ZC, Zhang HT, Dou KF. Differences in the properties and mirna expression profiles between side populations from hepatic cancer cells and normal liver cells. PLoS One. 2011;6:e23311. [PMID: 21826246 DOI: 10.1371/journal.pone.0023311] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
94 Sun S, Lee D, Leung GKK. Chemoresistance in Glioma. In: Lee NP, Cheng C, Luk JM, editors. New Advances on Disease Biomarkers and Molecular Targets in Biomedicine. Totowa: Humana Press; 2013. pp. 243-70. [DOI: 10.1007/978-1-62703-456-2_14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
95 Li J, Wan W, Chen T, Tong S, Jiang X, Liu W. miR-451 Silencing Inhibited Doxorubicin Exposure-Induced Cardiotoxicity in Mice. Biomed Res Int 2019;2019:1528278. [PMID: 31355248 DOI: 10.1155/2019/1528278] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
96 Eitan R, Kushnir M, Lithwick-yanai G, David MB, Hoshen M, Glezerman M, Hod M, Sabah G, Rosenwald S, Levavi H. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecologic Oncology 2009;114:253-9. [DOI: 10.1016/j.ygyno.2009.04.024] [Cited by in Crossref: 116] [Cited by in F6Publishing: 112] [Article Influence: 8.9] [Reference Citation Analysis]
97 Chen Y, Tsai Y, Fang Y, Tseng S. Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. Journal of Pediatric Surgery 2012;47:1797-805. [DOI: 10.1016/j.jpedsurg.2012.05.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
98 Du J, Liu S, He J, Liu X, Qu Y, Yan W, Fan J, Li R, Xi H, Fu W, Zhang C, Yang J, Hou J. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma. Oncotarget 2015;6:14993-5007. [PMID: 25915427 DOI: 10.18632/oncotarget.3802] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 9.8] [Reference Citation Analysis]
99 Haenisch S, Cascorbi I. miRNAs as mediators of drug resistance. Epigenomics 2012;4:369-81. [DOI: 10.2217/epi.12.39] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
100 Gomes BC, Rueff J, Rodrigues AS. MicroRNAs and Cancer Drug Resistance. Methods Mol Biol 2016;1395:137-62. [PMID: 26910073 DOI: 10.1007/978-1-4939-3347-1_9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
101 Zhu X, Li Y, Shen H, Li H, Long L, Hui L, Xu W. miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochim Biophys Sin (Shanghai) 2013;45:80-6. [PMID: 23178914 DOI: 10.1093/abbs/gms099] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
102 Yu AM, Tian Y, Tu MJ, Ho PY, Jilek JL. MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy. Drug Metab Dispos 2016;44:308-19. [PMID: 26566807 DOI: 10.1124/dmd.115.067470] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
103 Monroig PDC, Calin GA. Drug–MicroRNA Cross-Talk. MicroRNA in Regenerative Medicine. Elsevier; 2015. pp. 991-1016. [DOI: 10.1016/b978-0-12-405544-5.00038-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
104 Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 2009;37:2112-7. [PMID: 19581388 DOI: 10.1124/dmd.109.027680] [Cited by in Crossref: 174] [Cited by in F6Publishing: 165] [Article Influence: 13.4] [Reference Citation Analysis]
105 Bian HB, Pan X, Yang JS, Wang ZX, De W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res. 2011;30:20. [PMID: 21329503 DOI: 10.1186/1756-9966-30-20] [Cited by in Crossref: 104] [Cited by in F6Publishing: 104] [Article Influence: 9.5] [Reference Citation Analysis]
106 Alharbi M, Zuñiga F, Elfeky O, Guanzon D, Lai A, Rice GE, Perrin L, Hooper J, Salomon C. The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer. Endocrine-Related Cancer 2018;25:R663-85. [DOI: 10.1530/erc-18-0019] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
107 Feng X, Gan N, Zhang H, Li T, Cao Y, Hu F, Jiang Q. Ratiometric biosensor array for multiplexed detection of microRNAs based on electrochemiluminescence coupled with cyclic voltammetry. Biosens Bioelectron 2016;75:308-14. [PMID: 26332383 DOI: 10.1016/j.bios.2015.08.048] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 7.7] [Reference Citation Analysis]
108 Pofali P, Mondal A, Londhe V. Exosome as a Natural Gene Delivery Vector for Cancer Treatment. CCDT 2020;20:821-30. [DOI: 10.2174/1568009620666200924154149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
109 Chen T. Overcoming drug resistance by regulating nuclear receptors. Adv Drug Deliv Rev 2010;62:1257-64. [PMID: 20691230 DOI: 10.1016/j.addr.2010.07.008] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
110 de Souza PS, Faccion RS, Bernardo PS, Maia RC. Membrane microparticles: shedding new light into cancer cell communication. J Cancer Res Clin Oncol 2016;142:1395-406. [PMID: 26285684 DOI: 10.1007/s00432-015-2029-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
111 Zheng T, Wang J, Chen X, Liu L. Role of microRNA in anticancer drug resistance. Int J Cancer. 2010;126:2-10. [PMID: 19634138 DOI: 10.1002/ijc.24782] [Cited by in Crossref: 166] [Cited by in F6Publishing: 151] [Article Influence: 12.8] [Reference Citation Analysis]
112 Tian F, Han Y, Yan X, Zhong D, Yang G, Lei J, Li X, Wang X. Upregulation of microrna-451 increases the sensitivity of A549 cells to radiotherapy through enhancement of apoptosis. Thorac Cancer 2016;7:226-31. [PMID: 27042226 DOI: 10.1111/1759-7714.12318] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
113 Tong JL, Zhang CP, Nie F, Xu XT, Zhu MM, Xiao SD, Ran ZH. MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells. FEBS Lett. 2011;585:3560-3568. [PMID: 22036718 DOI: 10.1016/j.febslet.2011.10.021] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 5.2] [Reference Citation Analysis]
114 Yi D, Xu L, Wang R, Lu X, Sang J. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Cell Biol Int 2019;43:12-21. [PMID: 30444043 DOI: 10.1002/cbin.11071] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
115 Liao R, Lin Y, Zhu L. Molecular pathways involved in microRNA-mediated regulation of multidrug resistance. Mol Biol Rep 2018;45:2913-23. [DOI: 10.1007/s11033-018-4358-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
116 Hou Y, Fan L, Li H. Oncogenic miR-27a delivered by exosomes binds to SFRP1 and promotes angiogenesis in renal clear cell carcinoma. Mol Ther Nucleic Acids 2021;24:92-103. [PMID: 33738141 DOI: 10.1016/j.omtn.2020.11.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
117 Ansari MA, Thiruvengadam M, Farooqui Z, Rajakumar G, Sajid Jamal QM, Alzohairy MA, Almatroudi A, Alomary MN, Chung IM, Al-Suhaimi EA. Nanotechnology, in silico and endocrine-based strategy for delivering paclitaxel and miRNA: Prospects for the therapeutic management of breast cancer. Semin Cancer Biol 2021;69:109-28. [PMID: 31891780 DOI: 10.1016/j.semcancer.2019.12.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 4.3] [Reference Citation Analysis]
118 Ge A, Liu L, Deng X, Luo J, Xu Y. Exploring the Mechanism of Baicalin Intervention in Breast Cancer Based on MicroRNA Microarrays and Bioinformatics Strategies. Evid Based Complement Alternat Med 2021;2021:7624415. [PMID: 34966436 DOI: 10.1155/2021/7624415] [Reference Citation Analysis]
119 Izzotti A, Ceccaroli C, Geretto M, Ruggieri FG, Schenone S, Di Maria E. Predicting Response to Neoadjuvant Therapy in Colorectal Cancer Patients the Role of Messenger-and Micro-RNA Profiling. Cancers (Basel) 2020;12:E1652. [PMID: 32580435 DOI: 10.3390/cancers12061652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer--a brief overview. Adv Biol Regul. 2015;57:1-9. [PMID: 25294678 DOI: 10.1016/j.jbior.2014.09.013] [Cited by in Crossref: 304] [Cited by in F6Publishing: 324] [Article Influence: 38.0] [Reference Citation Analysis]
121 English DP, Menderes G, Black J, Schwab CL, Santin AD. Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer. Expert Rev Mol Diagn 2016;16:769-82. [PMID: 27169329 DOI: 10.1080/14737159.2016.1188692] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
122 Li H, Yang BB. Friend or foe: the role of microRNA in chemotherapy resistance. Acta Pharmacol Sin 2013;34:870-9. [PMID: 23624759 DOI: 10.1038/aps.2013.35] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 7.0] [Reference Citation Analysis]
123 Zou Z, Zou R, Zong D, Shi Y, Chen J, Huang J, Zhu J, Chen L, Bao X, Liu Y, Liu W, Huang W, Hu J, Chen Z, Lao X, Chen C, Huang X, Lu Y, Ni X, Fang D, Wu D, Lu S, Jiang M, Qiu C, Wu Y, Qiu Q, Dong Y, Su Y, Zhao C, Zhong Z, Cai J, Liang Y. miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression. J Cell Mol Med. 2017;21:1929-1943. [PMID: 28411377 DOI: 10.1111/jcmm.13114] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
124 Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, Wagar N, Yoon Y, Cho HT, Scala S, Shim H. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 2010;79:817-824. [PMID: 19883630 DOI: 10.1016/j.bcp.2009.10.017] [Cited by in Crossref: 224] [Cited by in F6Publishing: 213] [Article Influence: 17.2] [Reference Citation Analysis]
125 Pan YZ, Zhou A, Hu Z, Yu AM. Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos 2013;41:1744-51. [PMID: 23686318 DOI: 10.1124/dmd.113.052092] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 5.6] [Reference Citation Analysis]
126 Li MP, Hu YD, Hu XL, Zhang YJ, Yang YL, Jiang C, Tang J, Chen XP. MiRNAs and miRNA Polymorphisms Modify Drug Response. Int J Environ Res Public Health 2016;13:E1096. [PMID: 27834829 DOI: 10.3390/ijerph13111096] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
127 Zheng X, Zhang F, Zhao Y, Zhang J, Dawulieti J, Pan Y, Cui L, Sun M, Shao D, Li M, He K, Zhang M, Li J, Chen L. Self-assembled dual fluorescence nanoparticles for CD44-targeted delivery of anti-miR-27a in liver cancer theranostics. Theranostics 2018;8:3808-23. [PMID: 30083261 DOI: 10.7150/thno.25255] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
128 Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM, Fortes P. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells. 2011;29:1661-1671. [PMID: 21948564 DOI: 10.1002/stem.741] [Cited by in Crossref: 194] [Cited by in F6Publishing: 183] [Article Influence: 19.4] [Reference Citation Analysis]
129 Xu K, Liang X, Shen K, Cui D, Zheng Y, Xu J, Fan Z, Qiu Y, Li Q, Ni L. miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. Biochem J. 2012;446:291-300. [PMID: 22676135 DOI: 10.1042/bj20120386] [Cited by in Crossref: 51] [Cited by in F6Publishing: 29] [Article Influence: 5.1] [Reference Citation Analysis]
130 Liang Z, Ahn J, Guo D, Votaw JR, Shim H. MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharm Res. 2013;30:1008-1016. [PMID: 23184229 DOI: 10.1007/s11095-012-0936-9] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
131 Liu ZR, Song Y, Wan LH, Zhang YY, Zhou LM. Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3ζ, estrogen receptor α, and autophagy. Life Sci 2016;149:104-13. [PMID: 26896688 DOI: 10.1016/j.lfs.2016.02.059] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
132 Zou Z, Zhang J, Zhang H, Liu H, Li Z, Cheng D, Chen J, Liu L, Ni M, Zhang Y, Yao J, Zhou J, Fu J, Liang Y. 3-Methyladenine can depress drug efflux transporters via blocking the PI3K-AKT-mTOR pathway thus sensitizing MDR cancer to chemotherapy. J Drug Target 2014;22:839-48. [PMID: 25019701 DOI: 10.3109/1061186X.2014.936870] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
133 Li H, Hui L, Xu W, Shen H, Chen Q, Long L, Zhu X. Triptolide modulates the sensitivity of K562/A02 cells to adriamycin by regulating miR-21 expression. Pharm Biol. 2012;50:1233-1240. [PMID: 22957792 DOI: 10.3109/13880209.2012.665931] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
134 Bai Y, Liao H, Liu T, Zeng X, Xiao F, Luo L, Guo H, Guo L. MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-à-go-go (EAG1). Eur J Cancer 2013;49:710-24. [PMID: 22999387 DOI: 10.1016/j.ejca.2012.08.020] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
135 Cerovska E, Elsnerova K, Vaclavikova R, Soucek P. The role of membrane transporters in ovarian cancer chemoresistance and prognosis. Expert Opin Drug Metab Toxicol 2017;13:741-53. [PMID: 28511565 DOI: 10.1080/17425255.2017.1332179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
136 Garofalo M, Croce CM. MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat. 2013;16:47-59. [PMID: 23757365 DOI: 10.1016/j.drup.2013.05.001] [Cited by in Crossref: 100] [Cited by in F6Publishing: 99] [Article Influence: 11.1] [Reference Citation Analysis]
137 Sarkar FH, Li Y, Wang Z, Kong D, Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 2010;13:57-66. [PMID: 20236855 DOI: 10.1016/j.drup.2010.02.001] [Cited by in Crossref: 148] [Cited by in F6Publishing: 126] [Article Influence: 12.3] [Reference Citation Analysis]
138 Zhao W, Ning L, Wang L, Ouyang T, Qi L, Yang R, Wu Y. miR-21 inhibition reverses doxorubicin-resistance and inhibits PC3 human prostate cancer cells proliferation. Andrologia 2021;53:e14016. [PMID: 33598946 DOI: 10.1111/and.14016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
139 Chen Y, Xiao J, Zhang X, Bian X. MicroRNAs as key mediators of hepatic detoxification. Toxicology 2016;368-369:80-90. [PMID: 27501766 DOI: 10.1016/j.tox.2016.08.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
140 Weng N, Sun J, Kuang S, Lan H, He Q, Yang H, Zhang L, Xue H. MicroRNA-451 Aggravates Kainic Acid-induced Seizure and Neuronal Apoptosis by Targeting GDNF. Curr Neurovasc Res 2020;17:50-7. [PMID: 31870266 DOI: 10.2174/1567202617666191223150510] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
141 Banerjee N, Talcott S, Safe S, Mertens-Talcott SU. Cytotoxicity of pomegranate polyphenolics in breast cancer cells in vitro and vivo: potential role of miRNA-27a and miRNA-155 in cell survival and inflammation. Breast Cancer Res Treat. 2012;136:21-34. [PMID: 22941571 DOI: 10.1007/s10549-012-2224-0] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 7.8] [Reference Citation Analysis]
142 Guo L, Liu Y, Bai Y, Sun Y, Xiao F, Guo Y. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 2010;46:1692-702. [PMID: 20371173 DOI: 10.1016/j.ejca.2010.02.043] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 8.2] [Reference Citation Analysis]
143 Gu J, Zhu X, Li Y, Dong D, Yao J, Lin C, Huang K, Hu H, Fei J. miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Med Oncol 2011;28:211-8. [DOI: 10.1007/s12032-009-9413-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
144 Thakur PS, Khan AM, Talegaonkar S, Ahmad FJ, Iqbal Z. Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer. J Cancer Res Clin Oncol 2016;142:2073-106. [PMID: 27116692 DOI: 10.1007/s00432-016-2167-7] [Reference Citation Analysis]
145 Shin VY, Chu KM. MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol 2014; 20(30): 10432-10439 [PMID: 25132759 DOI: 10.3748/wjg.v20.i30.10432] [Cited by in CrossRef: 152] [Cited by in F6Publishing: 154] [Article Influence: 19.0] [Reference Citation Analysis]
146 Li Y, Meng Q, Yang M, Liu D, Hou X, Tang L, Wang X, Lyu Y, Chen X, Liu K, Yu AM, Zuo Z, Bi H. Current trends in drug metabolism and pharmacokinetics. Acta Pharm Sin B 2019;9:1113-44. [PMID: 31867160 DOI: 10.1016/j.apsb.2019.10.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
147 Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, Wang Z. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol. 2010;119:125-130. [PMID: 20624637 DOI: 10.1016/j.ygyno.2010.06.004] [Cited by in Crossref: 130] [Cited by in F6Publishing: 118] [Article Influence: 10.8] [Reference Citation Analysis]
148 Husted S, Søkilde R, Rask L, Cirera S, Busk PK, Eriksen J, Litman T. MicroRNA expression profiles associated with development of drug resistance in Ehrlich ascites tumor cells. Mol Pharm 2011;8:2055-62. [PMID: 21899346 DOI: 10.1021/mp200255d] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
149 Andorfer P, Rotheneder H. Regulation of the MDR1 promoter by E2F1 and EAPP. FEBS Lett 2013;587:1504-9. [PMID: 23542036 DOI: 10.1016/j.febslet.2013.03.026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
150 Fang Y, Shen H, Cao Y, Li H, Qin R, Chen Q, Long L, Zhu XL, Xie CJ, Xu WL. Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells. Braz J Med Biol Res 2014;47:60-9. [PMID: 24519092 DOI: 10.1590/1414-431X20133324] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
151 Gao P, Wei JM, Li PY, Zhang CJ, Jian WC, Zhang YH, Xing AY, Zhou GY. Screening of deoxyribozyme with high reversal efficiency against multidrug resistance in breast carcinoma cells. J Cell Mol Med 2011;15:2130-8. [PMID: 21155975 DOI: 10.1111/j.1582-4934.2010.01240.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
152 Chen Z, Ma T, Huang C, Zhang L, Lv X, Xu T, Hu T, Li J. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. Cell Signal 2013;25:2693-701. [PMID: 24018051 DOI: 10.1016/j.cellsig.2013.08.032] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 9.3] [Reference Citation Analysis]
153 Li F, Mahato RI. MicroRNAs and drug resistance in prostate cancers. Mol Pharm 2014;11:2539-52. [PMID: 24742219 DOI: 10.1021/mp500099g] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
154 Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, Hu T, Jiang L, Li J. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016;370:153-164. [PMID: 26499806 DOI: 10.1016/j.canlet.2015.10.010] [Cited by in Crossref: 379] [Cited by in F6Publishing: 368] [Article Influence: 54.1] [Reference Citation Analysis]
155 Koturbash I, Tolleson WH, Guo L, Yu D, Chen S, Hong H, Mattes W, Ning B. microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment. Biomark Med 2015;9:1153-76. [PMID: 26501795 DOI: 10.2217/bmm.15.89] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
156 do Imperio GE, Bloise E, Javam M, Lye P, Constantinof A, Dunk C, Dos Reis FM, Lye SJ, Gibb W, Ortiga-Carvalho TM, Matthews SG. Chorioamnionitis Induces a Specific Signature of Placental ABC Transporters Associated with an Increase of miR-331-5p in the Human Preterm Placenta. Cell Physiol Biochem 2018;45:591-604. [PMID: 29402780 DOI: 10.1159/000487100] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
157 Koturbash I, Beland FA, Pogribny IP. Role of microRNAs in the regulation of drug metabolizing and transporting genes and the response to environmental toxicants. Expert Opin Drug Metab Toxicol 2012;8:597-606. [PMID: 22435483 DOI: 10.1517/17425255.2012.673587] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
158 Oh J, Shin D, Lim KS, Lee S, Jung KH, Chu K, Hong KS, Shin KH, Cho JY, Yoon SH, Ji SC, Yu KS, Lee H, Jang IJ. Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity. Clin Pharmacol Ther 2014;95:608-16. [PMID: 24566733 DOI: 10.1038/clpt.2014.49] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
159 Madurantakam Royam M, Ramesh R, Shanker R, Sabarimurugan S, Kumarasamy C, Ramesh N, Gothandam KM, Baxi S, Gupta A, Krishnan S, Jayaraj R. miRNA Predictors of Pancreatic Cancer Chemotherapeutic Response: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E900. [PMID: 31252688 DOI: 10.3390/cancers11070900] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
160 Cui SY, Wang R, Chen LB. MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers. J Cell Mol Med 2013;17:1207-17. [PMID: 24106980 DOI: 10.1111/jcmm.12131] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
161 Hammad S, Mabondzo A, Hamoudi R, Harati R. Regulation of P-glycoprotein by miR-27a-3p at the Brain Endothelial Barrier. J Pharm Sci 2021:S0022-3549(21)00562-1. [PMID: 34695419 DOI: 10.1016/j.xphs.2021.10.021] [Reference Citation Analysis]
162 Toscano-Garibay JD, Aquino-Jarquin G. Regulation exerted by miRNAs in the promoter and UTR sequences: MDR1/P-gp expression as a particular case. DNA Cell Biol 2012;31:1358-64. [PMID: 22662865 DOI: 10.1089/dna.2012.1703] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
163 Margier M, Collet X, le May C, Desmarchelier C, André F, Lebrun C, Defoort C, Bluteau A, Borel P, Lespine A, Reboul E. ABCB1 (P-glycoprotein) regulates vitamin D absorption and contributes to its transintestinal efflux. FASEB J 2019;33:2084-94. [PMID: 30222077 DOI: 10.1096/fj.201800956R] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
164 Huang LL, Huang LW, Wang L, Tong BD, Wei Q, Ding XS. Potential role of miR-139-5p in cancer diagnosis, prognosis and therapy. Oncol Lett 2017;14:1215-22. [PMID: 28789336 DOI: 10.3892/ol.2017.6351] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
165 Borgie M, Ledoux F, Verdin A, Cazier F, Greige H, Shirali P, Courcot D, Dagher Z. Genotoxic and epigenotoxic effects of fine particulate matter from rural and urban sites in Lebanon on human bronchial epithelial cells. Environ Res 2015;136:352-62. [PMID: 25460656 DOI: 10.1016/j.envres.2014.10.010] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
166 Chistiakov DA, Chekhonin VP. Contribution of microRNAs to radio- and chemoresistance of brain tumors and their therapeutic potential. Eur J Pharmacol. 2012;684:8-18. [PMID: 22484336 DOI: 10.1016/j.ejphar.2012.03.031] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
167 Xiong G, Feng M, Yang G, Zheng S, Song X, Cao Z, You L, Zheng L, Hu Y, Zhang T, Zhao Y. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer. Cancer Lett. 2017;397:94-102. [PMID: 28254409 DOI: 10.1016/j.canlet.2017.02.020] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
168 Begicevic RR, Falasca M. ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance. Int J Mol Sci. 2017;18. [PMID: 29117122 DOI: 10.3390/ijms18112362] [Cited by in Crossref: 132] [Cited by in F6Publishing: 128] [Article Influence: 26.4] [Reference Citation Analysis]
169 Acunzo M, Croce CM. MicroRNA in Cancer and Cachexia--A Mini-Review. J Infect Dis 2015;212 Suppl 1:S74-7. [PMID: 26116737 DOI: 10.1093/infdis/jiv197] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
170 Zhu H, Wu H, Liu X, Li B, Chen Y, Ren X, Liu CG, Yang JM. Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. Autophagy. 2009;5:816-823. [PMID: 19535919 DOI: 10.4161/auto.9064] [Cited by in Crossref: 313] [Cited by in F6Publishing: 304] [Article Influence: 24.1] [Reference Citation Analysis]
171 Dai C, Bai Q, Zhang G, Cao Y, Shen J, Pei M, Yin CC. MicroRNA let-7f is down-regulated in patients with refractory acute myeloid leukemia and is involved in chemotherapy resistance of adriamycin-resistant leukemic cells. Leukemia & Lymphoma 2014;55:1645-8. [DOI: 10.3109/10428194.2013.847936] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
172 Li Y, Zhu X, Gu J, Hu H, Dong D, Yao J, Lin C, Fei J. Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis. Hematology 2010;15:215-21. [PMID: 20670480 DOI: 10.1179/102453310X12647083620840] [Cited by in Crossref: 43] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
173 Biersack B. Non-coding RNA/microRNA-modulatory dietary factors and natural products for improved cancer therapy and prevention: Alkaloids, organosulfur compounds, aliphatic carboxylic acids and water-soluble vitamins. Noncoding RNA Res 2016;1:51-63. [PMID: 30159411 DOI: 10.1016/j.ncrna.2016.09.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
174 Xie X, Li S, Zhu Y, Liu L, Pan Y, Wang J, Shi W, Song Y, Yang L, Gao L, Zang W, Li M. MicroRNA-27a/b mediates endothelin-1-induced PPARγ reduction and proliferation of pulmonary artery smooth muscle cells. Cell Tissue Res 2017;369:527-39. [PMID: 28484848 DOI: 10.1007/s00441-017-2625-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
175 Koh J, Itahana Y, Mendenhall IH, Low D, Soh EXY, Guo AK, Chionh YT, Wang LF, Itahana K. ABCB1 protects bat cells from DNA damage induced by genotoxic compounds. Nat Commun 2019;10:2820. [PMID: 31249297 DOI: 10.1038/s41467-019-10495-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
176 Lopes-Rodrigues V, Seca H, Sousa D, Sousa E, Lima RT, Vasconcelos MH. The network of P-glycoprotein and microRNAs interactions. Int J Cancer 2014;135:253-63. [PMID: 24122334 DOI: 10.1002/ijc.28500] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
177 Avci CB, Baran Y. Use of microRNAs in personalized medicine. Methods Mol Biol 2014;1107:311-25. [PMID: 24272446 DOI: 10.1007/978-1-62703-748-8_19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
178 Osanto S, Qin Y, Buermans HP, Berkers J, Lerut E, Goeman JJ, van Poppel H. Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS One 2012;7:e38298. [PMID: 22745662 DOI: 10.1371/journal.pone.0038298] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 8.5] [Reference Citation Analysis]
179 Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, Vanderburg CR, McLean PJ. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012;7:42. [PMID: 22920859 DOI: 10.1186/1750-1326-7-42] [Cited by in Crossref: 493] [Cited by in F6Publishing: 482] [Article Influence: 49.3] [Reference Citation Analysis]
180 Ménez C, Mselli-lakhal L, Foucaud-vignault M, Balaguer P, Alvinerie M, Lespine A. Ivermectin induces P-glycoprotein expression and function through mRNA stabilization in murine hepatocyte cell line. Biochemical Pharmacology 2012;83:269-78. [DOI: 10.1016/j.bcp.2011.10.010] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
181 Chen J, Shin VY, Siu MT, Ho JC, Cheuk I, Kwong A. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer. BMC Cancer 2016;16:887. [PMID: 27842518 DOI: 10.1186/s12885-016-2916-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 8.0] [Reference Citation Analysis]
182 Majchrzak-Celińska A, Baer-Dubowska W. Pharmacoepigenetics: an element of personalized therapy? Expert Opin Drug Metab Toxicol 2017;13:387-98. [PMID: 27860490 DOI: 10.1080/17425255.2017.1260546] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
183 Chen PS, Su JL, Hung MC. Dysregulation of microRNAs in cancer. J Biomed Sci 2012;19:90. [PMID: 23075324 DOI: 10.1186/1423-0127-19-90] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 9.2] [Reference Citation Analysis]
184 Shabani P, Izadpanah S, Aghebati-Maleki A, Baghbani E, Baghbanzadeh A, Fotouhi A, Bakhshinejad B, Aghebati-Maleki L, Baradaran B. Role of miR-142 in the pathogenesis of osteosarcoma and its potential as therapeutic approach. J Cell Biochem 2019;120:4783-93. [PMID: 30450580 DOI: 10.1002/jcb.27857] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
185 Long QZ, Du YF, Liu XG, Li X, He DL. miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma. Tumour Biol 2015;36:7017-26. [PMID: 25861751 DOI: 10.1007/s13277-015-3369-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
186 Palma J, Yaddanapudi SC, Pigati L, Havens MA, Jeong S, Weiner GA, Weimer KM, Stern B, Hastings ML, Duelli DM. MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Res. 2012;40:9125-9138. [PMID: 22772984 DOI: 10.1093/nar/gks656] [Cited by in Crossref: 149] [Cited by in F6Publishing: 150] [Article Influence: 14.9] [Reference Citation Analysis]
187 Feng F, Zhu X, Wang C, Chen L, Cao W, Liu Y, Chen Q, Xu W. Downregulation of hypermethylated in cancer-1 by miR-4532 promotes adriamycin resistance in breast cancer cells. Cancer Cell Int 2018;18:127. [PMID: 30202238 DOI: 10.1186/s12935-018-0616-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
188 Zhu H, Yue J, Pan Z, Wu H, Cheng Y, Lu H, Ren X, Yao M, Shen Z, Yang JM. Involvement of Caveolin-1 in repair of DNA damage through both homologous recombination and non-homologous end joining. PLoS One 2010;5:e12055. [PMID: 20700465 DOI: 10.1371/journal.pone.0012055] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
189 Yakusheva EN, Titov DS. Structure and Function of Multidrug Resistance Protein 1. Biochemistry Moscow 2018;83:907-29. [DOI: 10.1134/s0006297918080047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
190 Zheng H, Liu Z, Liu T, Cai Y, Wang Y, Lin S, Chen J, Wang J, Wang Z, Jiang B. Fas signaling promotes chemoresistance in gastrointestinal cancer by up-regulating P-glycoprotein. Oncotarget 2014;5:10763-77. [PMID: 25333257 DOI: 10.18632/oncotarget.2498] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
191 Zhang Y, Xu W, Ni P, Li A, Zhou J, Xu S. MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastric Cancer Cells by Targeting CAPNS1. Int J Biol Sci. 2016;12:1437-1447. [PMID: 27994509 DOI: 10.7150/ijbs.16529] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
192 Huang J, Chen Y, Li J, Zhang K, Chen J, Chen D, Feng B, Song H, Feng J, Wang R, Chen L. Notch-1 Confers Chemoresistance in Lung Adenocarcinoma to Taxanes through AP-1/microRNA-451 Mediated Regulation of MDR-1. Mol Ther Nucleic Acids 2016;5:e375. [PMID: 27727250 DOI: 10.1038/mtna.2016.82] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
193 Wang F, Liu W, Jin Y, Wang F, Ma J. Prenatal and neonatal exposure to perfluorooctane sulfonic acid results in aberrant changes in miRNA expression profile and levels in developing rat livers. Environ Toxicol 2015;30:712-23. [PMID: 24420840 DOI: 10.1002/tox.21949] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
194 Arrigoni E, Galimberti S, Petrini M, Danesi R, Di Paolo A. ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview. Expert Opin Drug Metab Toxicol 2016;12:1419-32. [PMID: 27459275 DOI: 10.1080/17425255.2016.1215423] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
195 Wang T, Zang WQ, Li M, Wang N, Zheng YL, Zhao GQ. Effect of miR-451 on the biological behavior of the esophageal carcinoma cell line EC9706. Dig Dis Sci. 2013;58:706-714. [PMID: 23053883 DOI: 10.1007/s10620-012-2395-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
196 Ingelman-Sundberg M, Zhong XB, Hankinson O, Beedanagari S, Yu AM, Peng L, Osawa Y. Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. Drug Metab Dispos 2013;41:1725-31. [PMID: 23918665 DOI: 10.1124/dmd.113.053157] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
197 Gupta SK, Singh P, Ali V, Verma M. Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy. Oncol Rev 2020;14:448. [PMID: 32676170 DOI: 10.4081/oncol.2020.448] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
198 Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, Yang D, Chen Z. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Resistance Updates 2016;27:14-29. [DOI: 10.1016/j.drup.2016.05.001] [Cited by in Crossref: 285] [Cited by in F6Publishing: 274] [Article Influence: 47.5] [Reference Citation Analysis]
199 Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Critical Reviews in Oncology/Hematology 2012;81:103-22. [DOI: 10.1016/j.critrevonc.2011.03.010] [Cited by in Crossref: 93] [Cited by in F6Publishing: 90] [Article Influence: 9.3] [Reference Citation Analysis]
200 Hui B, Chen X, Hui L, Xi R, Zhang X. Serum miRNA expression in patients with esophageal squamous cell carcinoma. Oncol Lett 2015;10:3008-12. [PMID: 26722280 DOI: 10.3892/ol.2015.3642] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
201 Shah P, Choi SW, Nagda R, Geczy R, Cho SK, Bhang YJ, Kim TH, Song TY, Lee PH, Kang JH, Thulstrup PW, Bjerrum MJ, Jung IL, Yang SW. The structural shift of a DNA template between a hairpin and a dimer tunes the emission color of DNA-templated AgNCs. Nanoscale 2018;10:20717-22. [PMID: 30398269 DOI: 10.1039/c8nr06186f] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
202 van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010;42:1282-90. [PMID: 20083225 DOI: 10.1016/j.biocel.2010.01.014] [Cited by in Crossref: 112] [Cited by in F6Publishing: 106] [Article Influence: 9.3] [Reference Citation Analysis]
203 Bolleyn J, De Kock J, Rodrigues RM, Vinken M, Rogiers V, Vanhaecke T. MicroRNAs as key regulators of xenobiotic biotransformation and drug response. Arch Toxicol 2015;89:1523-41. [PMID: 25079447 DOI: 10.1007/s00204-014-1314-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
204 Rodrigues AC, Curi R, Hirata MH, Hirata RDC. Decreased ABCB1 mRNA expression induced by atorvastatin results from enhanced mRNA degradation in HepG2 cells. European Journal of Pharmaceutical Sciences 2009;37:486-91. [DOI: 10.1016/j.ejps.2009.04.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
205 Wang H, Huang C, Zhao L, Zhang H, Yang JM, Luo P, Zhan BX, Pan Q, Li J, Wang BL. Histone deacetylase inhibitors regulate P-gp expression in colorectal cancer via transcriptional activation and mRNA stabilization. Oncotarget 2016;7:49848-58. [PMID: 27409663 DOI: 10.18632/oncotarget.10488] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
206 Feng SY, Dong CG, Wu WK, Wang XJ, Qiao J, Shao JF. Lentiviral expression of anti-microRNAs targeting miR-27a inhibits proliferation and invasiveness of U87 glioma cells. Mol Med Rep 2012;6:275-81. [PMID: 22614734 DOI: 10.3892/mmr.2012.915] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
207 Markova SM, Kroetz DL. ABCC4 is regulated by microRNA-124a and microRNA-506. Biochem Pharmacol 2014;87:515-22. [PMID: 24184504 DOI: 10.1016/j.bcp.2013.10.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
208 Wang Y, He Y, Qin Z, Jiang Y, Jin G, Ma H, Dai J, Chen J, Hu Z, Guan X, Shen H. Evaluation of functional genetic variants at 6q25.1 and risk of breast cancer in a Chinese population. Breast Cancer Res 2014;16:422. [PMID: 25116933 DOI: 10.1186/s13058-014-0422-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
209 Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li K, Zhou L, Sun Y, Li M, Zhou J, An Y, Wu K, Nie Y, Fan D. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene 2014;33:3267-76. [DOI: 10.1038/onc.2013.297] [Cited by in Crossref: 112] [Cited by in F6Publishing: 109] [Article Influence: 12.4] [Reference Citation Analysis]
210 Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol 2014;10:1337-54. [PMID: 25162314 DOI: 10.1517/17425255.2014.952630] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 9.6] [Reference Citation Analysis]
211 Nguyen HT, Tian G, Murph MM. Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise? Front Oncol 2014;4:71. [PMID: 24782983 DOI: 10.3389/fonc.2014.00071] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
212 Chen Z, Zhang L, Xia L, Jin Y, Wu Q, Guo H, Shang X, Dou J, Wu K, Nie Y. Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett. 2014;350:43-51. [PMID: 24759738 DOI: 10.1016/j.canlet.2014.04.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
213 Lu L, Ju F, Zhao H, Ma X. MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1. Biotechnol Lett 2015;37:2387-94. [DOI: 10.1007/s10529-015-1941-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
214 Wang Y, Wang Y, Qin Z, Cai S, Yu L, Hu H, Zeng S. The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer. Expert Opin Drug Metab Toxicol 2021;17:291-306. [PMID: 33544643 DOI: 10.1080/17425255.2021.1887139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
215 Wang R, Wang ZX, Yang JS, Pan X, De W, Chen LB. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene. 2011;30:2644-2658. [PMID: 21358675 DOI: 10.1038/onc.2010.642] [Cited by in Crossref: 217] [Cited by in F6Publishing: 204] [Article Influence: 19.7] [Reference Citation Analysis]
216 Liu J, Shang J, Mu X, Gao Z. Protective effect of down-regulated microRNA-27a mediating high thoracic epidural block on myocardial ischemia-reperfusion injury in mice through regulating ABCA1 and NF-κB signaling pathway. Biomedicine & Pharmacotherapy 2019;112:108606. [DOI: 10.1016/j.biopha.2019.108606] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
217 Svasti S, Masaki S, Penglong T, Abe Y, Winichagoon P, Fucharoen S, Umemura T. Expression of microRNA-451 in normal and thalassemic erythropoiesis. Ann Hematol. 2010;89:953-958. [PMID: 20461517 DOI: 10.1007/s00277-010-0980-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
218 Yu S, Wei Y, Xu Y, Zhang Y, Li J, Zhang J. Extracellular vesicles in breast cancer drug resistance and their clinical application. Tumour Biol 2016;37:2849-61. [PMID: 26797784 DOI: 10.1007/s13277-015-4683-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
219 Meng W, Jiang L, Lu L, Hu H, Yu H, Ding D, Xiao K, Zheng W, Guo H, Ma W. Anti-miR-155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis. Cell Biol Int 2012;36:653-9. [PMID: 22276743 DOI: 10.1042/CBI20100918] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
220 Zheng H, Liu JY, Song FJ, Chen KX. Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. Cancer Biol Med. 2013;10:123-130. [PMID: 24379986 DOI: 10.7497/j.issn.2095-3941.2013.03.001] [Cited by in F6Publishing: 24] [Reference Citation Analysis]
221 Huang D, Wang H, Liu R, Li H, Ge S, Bai M, Deng T, Yao G, Ba Y. miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer. J Cell Biochem. 2014;115:549-556. [PMID: 24122958 DOI: 10.1002/jcb.24689] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 5.9] [Reference Citation Analysis]
222 Lee ST, Jeon D, Chu K, Jung KH, Moon J, Sunwoo J, Park DK, Yang H, Park JH, Kim M, Roh JK, Lee SK. Inhibition of miR-203 Reduces Spontaneous Recurrent Seizures in Mice. Mol Neurobiol 2017;54:3300-8. [PMID: 27165289 DOI: 10.1007/s12035-016-9901-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
223 Gullà A, Di Martino MT, Gallo Cantafio ME, Morelli E, Amodio N, Botta C, Pitari MR, Lio SG, Britti D, Stamato MA, Hideshima T, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin Cancer Res 2016;22:1222-33. [PMID: 26527748 DOI: 10.1158/1078-0432.CCR-15-0489] [Cited by in Crossref: 70] [Cited by in F6Publishing: 50] [Article Influence: 10.0] [Reference Citation Analysis]
224 Hall KR, Fandy TE. Pharmacogenomics and Pharmacoepigenomics: Impact on Therapeutic Strategies. In: Pathak Y, editor. Genomics-Driven Healthcare. Singapore: Springer; 2018. pp. 227-38. [DOI: 10.1007/978-981-10-7506-3_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
225 Jaiswal R, Gong J, Sambasivam S, Combes V, Mathys JM, Davey R, Grau GE, Bebawy M. Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J 2012;26:420-9. [PMID: 21965597 DOI: 10.1096/fj.11-186817] [Cited by in Crossref: 76] [Cited by in F6Publishing: 80] [Article Influence: 6.9] [Reference Citation Analysis]
226 Zhao Y, Wang P, Meng J, Ji Y, Xu D, Chen T, Fan R, Yu X, Yao J, Dong C. MicroRNA-27a-3p Inhibits Melanogenesis in Mouse Skin Melanocytes by Targeting Wnt3a. Int J Mol Sci 2015;16:10921-33. [PMID: 26006230 DOI: 10.3390/ijms160510921] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
227 Wu X, Xiao H. miRNAs modulate the drug response of tumor cells. SCI CHINA SER C 2009;52:797-801. [DOI: 10.1007/s11427-009-0114-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
228 Dong Z, Zhong Z, Yang L, Wang S, Gong Z. MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Letters 2014;343:249-57. [DOI: 10.1016/j.canlet.2013.09.034] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 11.4] [Reference Citation Analysis]
229 Haier J, Ströse A, Matuszcak C, Hummel R. miR clusters target cellular functional complexes by defining their degree of regulatory freedom. Cancer Metastasis Rev 2016;35:289-322. [PMID: 26970968 DOI: 10.1007/s10555-016-9617-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
230 Wang Z, Lai J, Wang Y, Nie W, Guan X. The Hsa-miR-27a rs895819 (A>G) polymorphism and cancer susceptibility. Gene 2013;521:87-90. [PMID: 23524006 DOI: 10.1016/j.gene.2013.02.042] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
231 de Souza PS, Cruz AL, Viola JP, Maia RC. Microparticles induce multifactorial resistance through oncogenic pathways independently of cancer cell type. Cancer Sci 2015;106:60-8. [PMID: 25457412 DOI: 10.1111/cas.12566] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
232 Moitra K. Overcoming Multidrug Resistance in Cancer Stem Cells. Biomed Res Int. 2015;2015:635745. [PMID: 26649310 DOI: 10.1155/2015/635745] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 11.3] [Reference Citation Analysis]
233 Borel F, Han R, Visser A, Petry H, van Deventer SJ, Jansen PL, Konstantinova P. Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology. 2012;55:821-832. [PMID: 21932399 DOI: 10.1002/hep.24682] [Cited by in Crossref: 104] [Cited by in F6Publishing: 105] [Article Influence: 10.4] [Reference Citation Analysis]
234 Abbasi M, Lavasanifar A, Uludaˇ H. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer: RECENT ATTEMPTS AT RNAi-MEDIATED P-GLYCOPROTEIN. Med Res Rev 2013;33:33-53. [DOI: 10.1002/med.20244] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
235 Cojocneanu Petric R, Braicu C, Raduly L, Zanoaga O, Dragos N, Monroig P, Dumitrascu D, Berindan-Neagoe I. Phytochemicals modulate carcinogenic signaling pathways in breast and hormone-related cancers. Onco Targets Ther 2015;8:2053-66. [PMID: 26273208 DOI: 10.2147/OTT.S83597] [Cited by in Crossref: 42] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
236 Shi Y, Gao X, Hu Q, Li X, Xu J, Lu S, Liu Y, Xu C, Jiang D, Lin J, Xue A, Tan Y, Shen K, Hou Y. PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor. Lab Invest 2016;96:652-60. [PMID: 26950487 DOI: 10.1038/labinvest.2015.157] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
237 Gisel A, Valvano M, El Idrissi IG, Nardulli P, Azzariti A, Carrieri A, Contino M, Colabufo NA. miRNAs for the detection of multidrug resistance: overview and perspectives. Molecules 2014;19:5611-23. [PMID: 24786846 DOI: 10.3390/molecules19055611] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
238 Zhu X, Li Y, Xie C, Yin X, Liu Y, Cao Y, Fang Y, Lin X, Xu Y, Xu W. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer. 2014;135:1286-1296. [PMID: 24510775 DOI: 10.1002/ijc.28774] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 9.0] [Reference Citation Analysis]
239 Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol. 2009;75:1374-1379. [PMID: 19270061 DOI: 10.1124/mol.108.054163] [Cited by in Crossref: 219] [Cited by in F6Publishing: 206] [Article Influence: 16.8] [Reference Citation Analysis]
240 Witwer KW, Halushka MK. Toward the promise of microRNAs - Enhancing reproducibility and rigor in microRNA research. RNA Biol 2016;13:1103-16. [PMID: 27645402 DOI: 10.1080/15476286.2016.1236172] [Cited by in Crossref: 82] [Cited by in F6Publishing: 67] [Article Influence: 13.7] [Reference Citation Analysis]
241 Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 2012;180:2490-503. [PMID: 22521303 DOI: 10.1016/j.ajpath.2012.02.024] [Cited by in Crossref: 158] [Cited by in F6Publishing: 149] [Article Influence: 15.8] [Reference Citation Analysis]
242 Zang WQ, Yang X, Wang T, Wang YY, Du YW, Chen XN, Li M, Zhao GQ. MiR-451 inhibits proliferation of esophageal carcinoma cell line EC9706 by targeting CDKN2D and MAP3K1. World J Gastroenterol 2015; 21(19): 5867-5876 [PMID: 26019450 DOI: 10.3748/wjg.v21.i19.5867] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
243 Wu ZB, Li WQ, Lin SJ, Wang CD, Cai L, Lu JL, Chen YX, Su ZP, Shang HB, Yang WL. MicroRNA expression profile of bromocriptine-resistant prolactinomas. Mol Cell Endocrinol. 2014;395:10-18. [PMID: 25064468 DOI: 10.1016/j.mce.2014.07.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
244 Pogribny IP, Beland FA. Role of microRNAs in the regulation of drug metabolism and disposition genes in diabetes and liver disease. Expert Opin Drug Metab Toxicol 2013;9:713-24. [PMID: 23565851 DOI: 10.1517/17425255.2013.783817] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
245 Kim YW, Kim EY, Jeon D, Liu JL, Kim HS, Choi JW, Ahn WS. Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014;8:293-314. [PMID: 24591819 DOI: 10.2147/DDDT.S51969] [Cited by in Crossref: 16] [Cited by in F6Publishing: 51] [Article Influence: 2.0] [Reference Citation Analysis]
246 Manna A, Banerjee S, Khan P, Bhattacharya A, Das T. Contribution of nuclear events in generation and maintenance of cancer stem cells: revisiting chemo-resistance. Nucleus 2017;60:121-35. [DOI: 10.1007/s13237-017-0193-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
247 Wang F, Meng F, Wang L, Wong SC, Cho WC, Chan LW. Associations of mRNA:microRNA for the Shared Downstream Molecules of EGFR and Alternative Tyrosine Kinase Receptors in Non-small Cell Lung Cancer. Front Genet 2016;7:173. [PMID: 27790245 DOI: 10.3389/fgene.2016.00173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
248 Nobili S, Lapucci A, Landini I, Coronnello M, Roviello G, Mini E. Role of ATP-binding cassette transporters in cancer initiation and progression. Seminars in Cancer Biology 2020;60:72-95. [DOI: 10.1016/j.semcancer.2019.08.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
249 Montes-moreno S, Martinez N, Sanchez-espiridión B, Díaz Uriarte R, Rodriguez ME, Saez A, Montalbán C, Gomez G, Pisano DG, García JF, Conde E, Gonzalez-barca E, Lopez A, Mollejo M, Grande C, Martinez MA, Dunphy C, Hsi ED, Rocque GB, Chang J, Go RS, Visco C, Xu-monette Z, Young KH, Piris MA. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood 2011;118:1034-40. [DOI: 10.1182/blood-2010-11-321554] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
250 Zhu X, Luo X, Song Z, Jiang S, Long X, Gao X, Xie X, Zheng L, Wang H. miR-188-5p promotes oxaliplatin resistance by targeting RASA1 in colon cancer cells. Oncol Lett 2021;21:481. [PMID: 33968197 DOI: 10.3892/ol.2021.12742] [Reference Citation Analysis]
251 Singh NP, Singh UP, Guan H, Nagarkatti P, Nagarkatti M. Prenatal exposure to TCDD triggers significant modulation of microRNA expression profile in the thymus that affects consequent gene expression. PLoS One 2012;7:e45054. [PMID: 23024791 DOI: 10.1371/journal.pone.0045054] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
252 Abente EJ, Subramanian M, Ramachandran V, Najafi-Shoushtari SH. MicroRNAs in obesity-associated disorders. Arch Biochem Biophys 2016;589:108-19. [PMID: 26416722 DOI: 10.1016/j.abb.2015.09.018] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
253 Moitra K, Lou H, Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther. 2011;89:491-502. [PMID: 21368752 DOI: 10.1038/clpt.2011.14] [Cited by in Crossref: 173] [Cited by in F6Publishing: 159] [Article Influence: 15.7] [Reference Citation Analysis]
254 Balci S, Ayaz L, Gorur A, Yildirim Yaroglu H, Akbayir S, Dogruer Unal N, Bulut B, Tursen U, Tamer L. microRNA profiling for early detection of nonmelanoma skin cancer. Clin Exp Dermatol 2016;41:346-51. [DOI: 10.1111/ced.12736] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
255 Khordadmehr M, Jigari-Asl F, Ezzati H, Shahbazi R, Sadreddini S, Safaei S, Baradaran B. A comprehensive review on miR-451: A promising cancer biomarker with therapeutic potential. J Cell Physiol 2019;234:21716-31. [PMID: 31140618 DOI: 10.1002/jcp.28888] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
256 Zhong L, Wang JT, Wen D, Aris V, Soteropoulos P, Shapiro BA. Effective classification of microRNA precursors using feature mining and AdaBoost algorithms. OMICS 2013;17:486-93. [PMID: 23808606 DOI: 10.1089/omi.2013.0011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
257 Xu K, Liang X, Shen K, Sun L, Cui D, Zhao Y, Tian J, Ni L, Liu J. MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell Res. 2012;318:2168-2177. [PMID: 22677042 DOI: 10.1016/j.yexcr.2012.04.014] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 5.1] [Reference Citation Analysis]
258 Wang Z, Zhao K, Zhang Y, Duan X, Zhao Y. Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers. Pharm Res 2019;36:145. [PMID: 31396764 DOI: 10.1007/s11095-019-2669-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
259 Buhagiar A, Ayers D. Chemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastoma. Anal Cell Pathol (Amst). 2015;2015:150634. [PMID: 26258008 DOI: 10.1155/2015/150634] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
260 Ku P, Wang C, Nie X, Ou R, Li K. Regulation of pregnane-X-receptor and microRNAs on detoxification-related genes expressions in Mugilogobius abei under the exposure to diclofenac. Environmental Pollution 2018;233:395-406. [DOI: 10.1016/j.envpol.2017.10.080] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
261 Brenner B, Hoshen MB, Purim O, David MB, Ashkenazi K, Marshak G, Kundel Y, Brenner R, Morgenstern S, Halpern M, Rosenfeld N, Chajut A, Niv Y, Kushnir M. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol 2011; 17(35): 3976-3985 [PMID: 22046085 DOI: 10.3748/wjg.v17.i35.3976] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 62] [Article Influence: 6.1] [Reference Citation Analysis]
262 To KK, Robey RW, Knutsen T, Zhan Z, Ried T, Bates SE. Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol Cancer Ther. 2009;8:2959-2968. [PMID: 19825807 DOI: 10.1158/1535-7163.mct-09-0292] [Cited by in Crossref: 79] [Cited by in F6Publishing: 38] [Article Influence: 6.6] [Reference Citation Analysis]
263 Fang Y, Zhang L, Li Z, Li Y, Huang C, Lu X. MicroRNAs in DNA Damage Response, Carcinogenesis, and Chemoresistance. MiRNAs in Differentiation and Development. Elsevier; 2017. pp. 1-49. [DOI: 10.1016/bs.ircmb.2017.03.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
264 Zaheer U, Faheem M, Qadri I, Begum N, Yassine HM, Al Thani AA, Mathew S. Expression profile of MicroRNA: An Emerging Hallmark of Cancer. Curr Pharm Des 2019;25:642-53. [PMID: 30914015 DOI: 10.2174/1386207322666190325122821] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
265 Chistiakov DA, Chekhonin VP. Extracellular vesicles shed by glioma cells: pathogenic role and clinical value. Tumor Biol 2014;35:8425-38. [DOI: 10.1007/s13277-014-2262-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
266 Xiong HL, Zhou SW, Sun AH, He Y, Li J, Yuan X. MicroRNA197 reverses the drug resistance of fluorouracilinduced SGC7901 cells by targeting mitogenactivated protein kinase 1. Mol Med Rep. 2015;12:5019-5025. [PMID: 26151540 DOI: 10.3892/mmr.2015.4052] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
267 Glubb DM, Innocenti F. Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters. Wiley Interdiscip Rev Syst Biol Med 2011;3:299-313. [PMID: 20865777 DOI: 10.1002/wsbm.125] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
268 Allen DL, Loh AS. Posttranscriptional mechanisms involving microRNA-27a and b contribute to fast-specific and glucocorticoid-mediated myostatin expression in skeletal muscle. Am J Physiol Cell Physiol 2011;300:C124-37. [PMID: 20980549 DOI: 10.1152/ajpcell.00142.2010] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 6.4] [Reference Citation Analysis]
269 Jardim MJ, Fry RC, Jaspers I, Dailey L, Diaz-Sanchez D. Disruption of microRNA expression in human airway cells by diesel exhaust particles is linked to tumorigenesis-associated pathways. Environ Health Perspect 2009;117:1745-51. [PMID: 20049127 DOI: 10.1289/ehp.0900756] [Cited by in Crossref: 133] [Cited by in F6Publishing: 127] [Article Influence: 10.2] [Reference Citation Analysis]
270 Chiocca EA, Lawler SE. The Many Functions of MicroRNAs in Glioblastoma. World Neurosurgery 2010;73:598-601. [DOI: 10.1016/j.wneu.2010.06.047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
271 Kumar S, Kumar A, Shah PP, Rai SN, Panguluri SK, Kakar SS. MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 2011;4:17. [PMID: 21939554 DOI: 10.1186/1757-2215-4-17] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
272 Wang L, Ye X, Liu Y, Wei W, Wang Z. Aberrant regulation of FBW7 in cancer. Oncotarget 2014;5:2000-15. [PMID: 24899581 DOI: 10.18632/oncotarget.1859] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 8.7] [Reference Citation Analysis]
273 To KK. MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. J Biomed Sci 2013;20:99. [PMID: 24358977 DOI: 10.1186/1423-0127-20-99] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
274 Mishra PJ. The miRNA-drug resistance connection: a new era of personalized medicine using noncoding RNA begins. Pharmacogenomics 2012;13:1321-4. [PMID: 22966880 DOI: 10.2217/pgs.12.121] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
275 Bates DJ, Li N, Liang R, Sarojini H, An J, Masternak MM, Bartke A, Wang E. MicroRNA regulation in Ames dwarf mouse liver may contribute to delayed aging. Aging Cell 2010;9:1-18. [PMID: 19878148 DOI: 10.1111/j.1474-9726.2009.00529.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 5.7] [Reference Citation Analysis]
276 Vesela E, Chroma K, Turi Z, Mistrik M. Common Chemical Inductors of Replication Stress:  Focus on Cell-Based Studies. Biomolecules 2017;7:E19. [PMID: 28230817 DOI: 10.3390/biom7010019] [Cited by in Crossref: 41] [Cited by in F6Publishing: 8] [Article Influence: 8.2] [Reference Citation Analysis]
277 Jaiswal R, Luk F, Gong J, Mathys JM, Grau GE, Bebawy M. Microparticle conferred microRNA profiles--implications in the transfer and dominance of cancer traits. Mol Cancer. 2012;11:37. [PMID: 22682234 DOI: 10.1186/1476-4598-11-37] [Cited by in Crossref: 77] [Cited by in F6Publishing: 78] [Article Influence: 7.7] [Reference Citation Analysis]
278 Haenisch S, Werk AN, Cascorbi I. MicroRNAs and their relevance to ABC transporters. Br J Clin Pharmacol 2014;77:587-96. [PMID: 24645868 DOI: 10.1111/bcp.12251] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
279 Sampson VB, Yoo S, Kumar A, Vetter NS, Kolb EA. MicroRNAs and Potential Targets in Osteosarcoma: Review. Front Pediatr 2015;3:69. [PMID: 26380245 DOI: 10.3389/fped.2015.00069] [Cited by in Crossref: 90] [Cited by in F6Publishing: 99] [Article Influence: 12.9] [Reference Citation Analysis]
280 Bai H, Wu S. miR-451: A Novel Biomarker and Potential Therapeutic Target for Cancer. Onco Targets Ther 2019;12:11069-82. [PMID: 31908476 DOI: 10.2147/OTT.S230963] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
281 Wang SJ, Cao YF, Yang ZQ, Jiang ZY, Cai B, Guo J, Zhang S, Zhang XL, Gao F. MicroRNA-93-5p increases multidrug resistance in human colorectal carcinoma cells by downregulating cyclin dependent kinase inhibitor 1A gene expression. Oncol Lett 2017;13:722-30. [PMID: 28356951 DOI: 10.3892/ol.2016.5463] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
282 Ruiz Puentes P, Valderrama N, González C, Daza L, Muñoz-Camargo C, Cruz JC, Arbeláez P. PharmaNet: Pharmaceutical discovery with deep recurrent neural networks. PLoS One 2021;16:e0241728. [PMID: 33901196 DOI: 10.1371/journal.pone.0241728] [Reference Citation Analysis]
283 Freimund AE, Beach JA, Christie EL, Bowtell DD. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer. Hematology/Oncology Clinics of North America 2018;32:983-96. [DOI: 10.1016/j.hoc.2018.07.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
284 Hosseinahli N, Aghapour M, Duijf PHG, Baradaran B. Treating cancer with microRNA replacement therapy: A literature review. J Cell Physiol. 2018;233:5574-5588. [PMID: 29521426 DOI: 10.1002/jcp.26514] [Cited by in Crossref: 151] [Cited by in F6Publishing: 148] [Article Influence: 37.8] [Reference Citation Analysis]
285 Garajová I, Le Large TY, Frampton AE, Rolfo C, Voortman J, Giovannetti E. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Biomed Res Int. 2014;2014:678401. [PMID: 25250326 DOI: 10.1155/2014/678401] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
286 Andorfer CA, Necela BM, Thompson EA, Perez EA. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends in Molecular Medicine 2011;17:313-9. [DOI: 10.1016/j.molmed.2011.01.006] [Cited by in Crossref: 142] [Cited by in F6Publishing: 133] [Article Influence: 12.9] [Reference Citation Analysis]
287 Pourbagheri-Sigaroodi A, Bashash D, Safaroghli-Azar A, Farshi-Paraasghari M, Momeny M, Mansoor FN, Ghaffari SH. Contributory role of microRNAs in anti-cancer effects of small molecule inhibitor of telomerase (BIBR1532) on acute promyelocytic leukemia cell line. Eur J Pharmacol 2019;846:49-62. [PMID: 30658112 DOI: 10.1016/j.ejphar.2019.01.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
288 Jadideslam G, Ansarin K, Sakhinia E, Babaloo Z, Abhari A, Ghahremanzadeh K, Khalili M, Radmehr R, Kabbazi A. Diagnostic biomarker and therapeutic target applications of miR-326 in cancers: A systematic review. J Cell Physiol 2019;234:21560-74. [PMID: 31069801 DOI: 10.1002/jcp.28782] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
289 Li Z, Wang H, Chen L, Wang L, Liu X, Ru C, Song A. Identification and characterization of novel and differentially expressed microRNAs in peripheral blood from healthy and mastitis Holstein cattle by deep sequencing. Anim Genet 2014;45:20-7. [PMID: 24308606 DOI: 10.1111/age.12096] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
290 Huang X, Huang F, Yang D, Dong F, Shi X, Wang H, Zhou X, Wang S, Dai S. Expression of microRNA-122 contributes to apoptosis in H9C2 myocytes. J Cell Mol Med 2012;16:2637-46. [PMID: 22453009 DOI: 10.1111/j.1582-4934.2012.01577.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
291 Sato S, Itamochi H. Ovarian Cancer and Drug Resistance. Curr Obstet Gynecol Rep 2015;4:18-25. [DOI: 10.1007/s13669-014-0111-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
292 Genovese I, Ilari A, Assaraf YG, Fazi F, Colotti G. Not only P-glycoprotein: Amplification of the ABCB1- containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resistance Updates 2017;32:23-46. [DOI: 10.1016/j.drup.2017.10.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 11.2] [Reference Citation Analysis]
293 Li X, Pan YZ, Seigel GM, Hu ZH, Huang M, Yu AM. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol 2011;81:783-92. [PMID: 21219875 DOI: 10.1016/j.bcp.2010.12.018] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 6.8] [Reference Citation Analysis]
294 de Klerk DJ, Honeywell RJ, Jansen G, Peters GJ. Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. Cancers (Basel). 2018;10. [PMID: 30544701 DOI: 10.3390/cancers10120503] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
295 Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, Sarkar FH. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 2010;13:109-18. [PMID: 20692200 DOI: 10.1016/j.drup.2010.07.001] [Cited by in Crossref: 237] [Cited by in F6Publishing: 230] [Article Influence: 19.8] [Reference Citation Analysis]
296 Sotillo E, Thomas-Tikhonenko A. Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther. 2011;131:18-32. [PMID: 21514318 DOI: 10.1016/j.pharmthera.2011.04.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
297 Raza U, Zhang JD, Sahin O. MicroRNAs: master regulators of drug resistance, stemness, and metastasis. J Mol Med (Berl). 2014;92:321-336. [PMID: 24509937 DOI: 10.1007/s00109-014-1129-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 5.5] [Reference Citation Analysis]
298 Tombolan L, Zampini M, Casara S, Boldrin E, Zin A, Bisogno G, Rosolen A, De Pittà C, Lanfranchi G. MicroRNA-27a Contributes to Rhabdomyosarcoma Cell Proliferation by Suppressing RARA and RXRA. PLoS One 2015;10:e0125171. [PMID: 25915942 DOI: 10.1371/journal.pone.0125171] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
299 Chen J, Tian W, Cai H, He H, Deng Y. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol 2012;29:2527-34. [PMID: 22101791 DOI: 10.1007/s12032-011-0117-4] [Cited by in Crossref: 90] [Cited by in F6Publishing: 83] [Article Influence: 8.2] [Reference Citation Analysis]
300 Rodrigues AC, Li X, Radecki L, Pan YZ, Winter JC, Huang M, Yu AM. MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines. Biopharm Drug Dispos. 2011;32:355-367. [PMID: 21796641 DOI: 10.1002/bdd.764] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
301 Hess A, Müer A, Mairinger FD, Weichert W, Stenzinger A, Hummel M, Budach V, Tinhofer I. MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. European Journal of Cancer 2017;77:3-12. [DOI: 10.1016/j.ejca.2017.02.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
302 Nakano M, Nakajima M. Significance of A-to-I RNA editing of transcripts modulating pharmacokinetics and pharmacodynamics. Pharmacology & Therapeutics 2018;181:13-21. [DOI: 10.1016/j.pharmthera.2017.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
303 Jiang L, Meng W, Zeng J, Hu H, Lu L. MiR-34c oligonucleotide enhances chemosensitivity of Ishikawa cell to cisplatin by inducing apoptosis. Cell Biol Int 2013;37:577-83. [PMID: 23412924 DOI: 10.1002/cbin.10074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
304 Gabra MM, Salmena L. microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview. Front Oncol 2017;7:255. [PMID: 29164055 DOI: 10.3389/fonc.2017.00255] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
305 Xu C, Cheng H, Li N, Zhou N, Tang X. Relationship between microRNA-27a and efficacy of neoadjuvant chemotherapy in gastric cancer and its mechanism in gastric cancer cell growth and metastasis. Biosci Rep 2019;39:BSR20181175. [PMID: 30902884 DOI: 10.1042/BSR20181175] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
306 Paseban M, Marjaneh RM, Banach M, Riahi MM, Bo S, Sahebkar A. Modulation of microRNAs by aspirin in cardiovascular disease. Trends in Cardiovascular Medicine 2020;30:249-54. [DOI: 10.1016/j.tcm.2019.08.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
307 Pomatto MAC, Bussolati B, D'Antico S, Ghiotto S, Tetta C, Brizzi MF, Camussi G. Improved Loading of Plasma-Derived Extracellular Vesicles to Encapsulate Antitumor miRNAs. Mol Ther Methods Clin Dev. 2019;13:133-144. [PMID: 30788382 DOI: 10.1016/j.omtm.2019.01.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 21.3] [Reference Citation Analysis]
308 Danza K, Silvestris N, Simone G, Signorile M, Saragoni L, Brunetti O, Monti M, Mazzotta A, De Summa S, Mangia A, Tommasi S. Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. Cancer Biol Ther. 2016;17:400-406. [PMID: 26793992 DOI: 10.1080/15384047.2016.1139244] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
309 Su JL, Chen PB, Chen YH, Chen SC, Chang YW, Jan YH, Cheng X, Hsiao M, Hung MC. Downregulation of microRNA miR-520h by E1A contributes to anticancer activity. Cancer Res 2010;70:5096-108. [PMID: 20501832 DOI: 10.1158/0008-5472.CAN-09-4148] [Cited by in Crossref: 48] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
310 Yuan X, Ma R, Yang S, Jiang L, Wang Z, Zhu Z, Li H. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1. Cell Cycle 2019;18:1660-9. [PMID: 31204563 DOI: 10.1080/15384101.2019.1632138] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
311 Leng H, Zang WQ, Wang T, Wang YY, Ma J, Zhao GQ. Overexpression of miR-451 inhibits cell proliferation and invasion and promotes apoptosis in human esophageal carcinoma cell line EC9706. Shijie Huaren Xiaohua Zazhi 2012; 20(15): 1323-1327 [DOI: 10.11569/wcjd.v20.i15.1323] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
312 Czerwinska P, Kaminska B. Regulation of breast cancer stem cell features. Contemp Oncol (Pozn) 2015;19:A7-A15. [PMID: 25691826 DOI: 10.5114/wo.2014.47126] [Cited by in Crossref: 8] [Cited by in F6Publishing: 29] [Article Influence: 1.1] [Reference Citation Analysis]